Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of NK cell immunotherapy in children with high-risk neuroblastoma
NL-OMON33301Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2010
- Countries
- 1
01
Overview
Open-label, single-arm trial of Natural Killer Cells in neuroblastoma, sponsored by Amsterdam University Medical Center. Primary endpoints: Expression of NK-cell receptor ligands on neuroblastoma cells, NK-cell sensitivity of primary neuroblastoma cells and 2 more. Started Oct 2010; status: active, not recruiting.
02
Drugs
Natural Killer Cells
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NL-OMON33301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33301.